Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Abasaglar ® (basal insulin glargine)
Is Abasaglar® (insulin glargine) safe to use while breastfeeding?
There are no data on the presence of Abasaglar in breast milk nor on its effects on the breastfed infant.
Abasaglar Use While Breast-Feeding
It is unknown whether insulin glargine is excreted in human milk.1
No metabolic effects of ingested insulin glargine on the breast-fed newborn or infant are anticipated since insulin glargine, as a peptide, is digested into amino acids in the human gastrointestinal tract.1
Breast-feeding women may require adjustments in insulin dose and diet.1
1Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Date of Last Review: April 06, 2021